• Advancing gastrointestinal health naturally

    Our Gastrointestinal ReProgramming (GaRP) over-the-counter medicine is focused on addressing the chronic symptoms associated with irritable bowel syndrome (IBS) and the inflammatory bowel diseases (IBD). More >>

  • Anatara Investor Presentation

    Anatara Lifesciences provides an update to shareholders and investors. Commencing clinical trials from Q1 FY22, with fast potential speed to market. More>>

  • Anatara Animal Health Update

    Anatara Lifesciences provides an update on initiation of a challenge study in poultry with the recently developed bromelain-based formulation (ANR-pf) in collaboration with the University of New England’s Poultry Hub Australia. More >>

  • Summary of GaRP preclinical studies

    Anatara’s Gastrointestinal ReProgramming (GaRP) product successfully completes preclinical program – provides strong scientific proof that the unique over-the-counter medicine may be the breakthrough product so desperately needed by patients suffering chronic bowel conditions. More >>

Company description

Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a specialist life sciences company with expertise in developing products for animal and human health. We are currently focused on building a pipeline of evidence-based, over-the-counter gastrointestinal health products, through in-house development and in-licencing and distribution opportunities.

Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Recent coverage



More Events


Investors Home